This content is in French.
Depression: Shining a Light on Future Treatments
23 janvier 2025
Major Depressive Disorder
(MDD) is one of the leading causes of disability worldwide, significantly
impacting the quality of life for millions. Affecting approximately 322 million
individuals globally, it represents a substantial burden for both individuals
and healthcare systems. In some European countries, its prevalence can reach up
to 21%, underscoring the widespread nature of this condition.
This is particularly true because MDD is a complex and heterogeneous disease, characterized by a wide variety of symptoms and clinical trajectories. This variability makes treatment especially challenging, as nearly 30% of patients do not respond to traditional therapies (antidepressants, psychotherapy). These cases of treatment-resistant depression call for an urgent exploration of alternative therapeutic solutions targeting biological mechanisms not addressed by current treatments.
This is particularly true because MDD is a complex and heterogeneous disease, characterized by a wide variety of symptoms and clinical trajectories. This variability makes treatment especially challenging, as nearly 30% of patients do not respond to traditional therapies (antidepressants, psychotherapy). These cases of treatment-resistant depression call for an urgent exploration of alternative therapeutic solutions targeting biological mechanisms not addressed by current treatments.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Njenga, C., et al. (2024). New and emerging treatments for major depressive disorder. bmj, 386
View the source
